Neuroleptic Malignant Syndrome

OVERVIEW

life-threatening extrapyramidal complication of using neuroleptic drugs

PATHOPHYSIOLOGY

  • ? -> 2 theories
  • neuroleptic-induced alteration of central neuroregulatory mechanisms -> impaired heat dissipation
  • abnormal reaction of predisposed skeletal muscle (like MH)

CLINICAL FEATURES

  • develops over 24-72 hrs
  • hyperthermia
  • rigidity
  • rhabdomyolysis
  • RESP – decreased chest wall compliance, tachypnoea, pulmonary infection
  • NEURO – dyskinesia, dysarthria, parkinsonianism, agitation, stupour, coma, GTC seizures, chorea, babinski, chorea, trismus
  • RENAL – renal faliure
  • CVS – tachycardia, high BP, autonomic dysfunction
  • HAEM – high WCC
  • HEPATIC – increased LFT’s

RISK FACTORS

  • phenothiazines (chlorpromazine, promethazine)
  • butyrophenones (droperidol, haloperidol)
  • thioxanthenes (chlorprothixene)
  • benzamides (sulpiride)
  • clozapine
  • respiradone
  • abrupt ceasing of neuroleptic or PD drugs
  • alcoholics
  • exhaustion
  • dehydration
  • malnutrition

Important differences between serotonin syndrome and neuroleptic malignant syndrome:

(1) NMS is a idiosyncratic reaction after prolonged exposure to neuroleptics or after withdrawal of a dopamine receptor agonist.
(2) NMS usually develops over days or weeks
(3) NMS usually accompanied by hyperthermia, severe muscle rigidity and rhabdomyolysis (not mydriasis, diarrhoea, hyperreflexia, myoclonus)
(4) NMS frequently associated with multi-organ failure

MANAGEMENT

Goals

(1) early recognition
(2) withdrawal of precipitents
(3) supportive care

Resuscitation

  • airway assessment and securing if not patent (jaw trismus)
  • hyperventilation
  • liberal fluid resuscitation
  • cool
  • cardiovascular support (may require cautious beta-blockade)
  • paralyse -> rigidity will respond to NDNMBS

Electrolytes and Acid-base

  • hypermetabolic syndrome
  • may require bicarbonate therapy if there is documented severe acidosis that is unresponsive to specific treatment

Specific Therapy

  • bromocriptine
  • amantidine
  • dantrolene

Underlying cause

  • stop agents

CCC Toxicology Series

CCC 700 6

Critical Care

Compendium

Chris is an Intensivist and ECMO specialist at The Alfred ICU, where he is Deputy Director (Education). He is a Clinical Adjunct Associate Professor at Monash University, the Lead for the  Clinician Educator Incubator programme, and a CICM First Part Examiner.

He is an internationally recognised Clinician Educator with a passion for helping clinicians learn and for improving the clinical performance of individuals and collectives. He was one of the founders of the FOAM movement (Free Open-Access Medical education) has been recognised for his contributions to education with awards from ANZICS, ANZAHPE, and ACEM.

His one great achievement is being the father of three amazing children.

On Bluesky, he is @precordialthump.bsky.social and on the site that Elon has screwed up, he is @precordialthump.

| INTENSIVE | RAGE | Resuscitology | SMACC

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.